This paper is in the following e-collection/theme issue:

Diabetes Surveillance and Epidemiology (27) Diabetes (180) Health Services Research (460) Cardiovascular Disease Prevention (131) Secondary Use of Clinical Data for Research and Surveillance (358)

Published on in Vol 9 (2024)

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/58137, first published .
Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Comparing Insulin Against Glucagon-Like Peptide-1 Receptor Agonists, Dipeptidyl Peptidase-4 Inhibitors, and Sodium-Glucose Cotransporter 2 Inhibitors on 5-Year Incident Heart Failure Risk for Patients With Type 2 Diabetes Mellitus: Real-World Evidence Study Using Insurance Claims

Authors of this article:

Xuan Wang1 Author Orcid Image ;   Anna M Plantinga2 Author Orcid Image ;   Xin Xiong3 Author Orcid Image ;   Sara J Cromer4 Author Orcid Image ;   Clara-Lea Bonzel5 Author Orcid Image ;   Vidul Panickan5 Author Orcid Image ;   Rui Duan3 Author Orcid Image ;   Jue Hou6 Author Orcid Image ;   Tianxi Cai3 Author Orcid Image
Article Authors Cited by Tweetations Metrics
All Time | Last Month | Last Six Months | Last Year
There are currently no tweets available for this article within the specified range.